Key result
Cancer and antitumor therapies are linked to higher arterial thromboembolism risk, potentially signaling undetected malignancies.
Why the study?
Understanding the process of arterial thromboembolism is critical for properly managing cancer patients during and after treatment to prevent life-threatening complications.
Cancer and its treatments increase the risk of arterial thromboembolism, which can also serve as an early indicator of undiagnosed malignancies.
May prompt malignancy evaluation after unexplained arterial thromboembolism; hypothesis-generating and requires prospective validation.
Arterial thromboembolic complications are rare in cancer patients. Malignant neoplasms and antitumor therapy contribute to an increased risk of arterial thromboembolism, ischemic stroke, and myocardial infarction. The development of arterial thromboembolism in people without a history of cancer may be a harbinger of as yet undetected malignancies. Understanding the process of arterial thromboembolism is an important prerequisite for the proper management of patients with cancer during and after treatment in order to prevent life-threatening complications.
No takes yet. Share an insight, caveat, or question.
Kozlov et al. (2025) conducted a review in Cancer and arterial thromboembolism. Malignant neoplasms and antitumor therapy increase the risk of arterial thromboembolism, ischemic stroke, and myocardial infarction, which may also serve as a harbinger of undetected malignancies.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: